Lipoprotein lipase (LPL) plays a crucial role in the regulation of lipoprotein metabolism by hydrolysing the core triglycerides of circulating chylomicrons and VLDL. Human, bovine, mouse, and guinea pig complementary DNA clones have recently been isolated and the organization of the human LPL gene is now known to comprise 10 exons spanning -30 kb.
Introduction
The enzyme lipoprotein lipase (LPL)' plays a pivotal role in the hydrolysis of triacylglycerols in plasma lipoproteins. The action of LPL occurs at the luminal surface of vascular endothelium to which it is anchored by a membrane-bound heparan sulfate glycosaminoglycan chain. The synthesis of LPL, polymerase chain reaction; RFLP, restriction fragment length polymorphism.
however, occurs in parenchymal cells, primarily adipose tissue and skeletal muscle, from which it is secreted and transported by an unknown mechanism to the intimal surface ofthe vascular endothelium. Active LPL is a noncovalently linked homodimer of two glycoprotein chains each of 50 kD (1) . For optimal activity against long-chain triglycerides, LPL requires the presence and binding of apo CII.
Human (2) , bovine (3), mouse (4) , and guinea pig (5) complementary cDNA clones of LPL show homology of -83% (6) . The human gene spans -30 kb on the short arm of chromosome 8 (7) and comprises 10 exons with exon 10 specifying the entire 3' untranslated sequence (8) .
There are at least six important functional domains in the LPL protein that are likely to be coded for by different exons or combinations of exons in the LPL gene. The 27-amino acid signal peptide is encoded by exon 1, which is cleaved from the mature-protein after the second ofthree alanine residues (6, 8) . The functional sites in the LPL protein include a domain for the interaction with apo CII, one for binding to membrane bound heparan sulfate, a catalytic site, a site promoting interaction with the other glycoprotein chain to form an active dimer and an interfacial lipid binding site. Our goal is to obtain new insights into the relationship between the structure and function of LPL by defining the molecular basis of naturally occurring mutations in the LPL gene.
We have previously described a deletion and duplication in the LPL gene each of which led to undetectable levels of LPL activity and LPL mass in plasma (9, 10) . However, not all mutations would be expected to affect the LPL protein in the same way. The LPL protein may be catalytically defective but respond with a significant appearance of mass in plasma after heparin injection similar to that seen in normal persons. On the other hand, mutations that also effect heparan sulphate binding might result in elevated levels of LPL in preheparin plasma and show no increase after heparin injection (1 1).
The clinical syndrome of LPL deficiency presents with abdominal pain, pancreatitis, eruptive xanthomata, hepatosplenomegaly, and failure to thrive (12) . LPL deficiency is a rare disorder occurring with a frequency of at least 1:1 million in most parts of the world (12) . However, a significantly increased frequency of this disease has been found in French Canadians in certain regions ofQuebec where the frequency of affected persons reaches between 1:5,000 and 1:10,000 with carrier frequencies of up to 1:40 (13 Measurement ofLPL activity and mass. Plasma postheparin LPL activity was measured 10 min after a heparin bolus (60 IU/kg) after an overnight fast by using a triglyceride-phosphatidylcholine emulsion as previously described ( 14) . LPL activity was calculated as the activity in whole plasma inhibited by an MAb (5D2) added to plasma (14) and is expressed as nanomoles of fatty acids released per minute per milliliter of plasma. The LPL preheparin and mass released into plasma by heparin were measured by ELISA using MAb 5D2 and is reported as nanograms/milliliter (15) . The (Fig. 1) . The reactions were denatured at 94'C for 1 min and annealed for 1 min at 50 or 60'C for different oligomers as shown in Table I (17) and hybridized as previously described (9) . The digested DNA was run on a 0.7% agarose gel, depurinated, denatured, and transferred to nylon filters (Nytran, Schleicher & Schuell, Keene, NH). Prehybridization and hybridization were performed in the solutions as described previously (9) . A 1.36-kb cDNA clone (HLP26) that corresponds to nucleotides 271-1,630 of the published cDNA sequence was used in the hybridization reactions (2, 9) .
Results
Mutation analysis. Pedigrees were constructed for all probands. No (Table IV) . Details concerning a subset ofthis family have been published previously (18, 19) . The mutation at residue 188 of the LPL protein, occurs in a region that shows complete homology with the predicted amino acid sequence of guinea pig, mouse, and bovine LPL (20) .
Protein results. Pre-and postheparin plasma LPL from 44 affected persons with LPL deficiency were assessed for LPL activity and mass. We selected all unrelated probands who had deficiency of LPL activity. 13 probands had at least one mutation at residue 188 (Table V) pected to result in a very high frequency for this disease in the population. Evidence in support ofthis is the high frequency of tyrosinemia (22), vitamin D deficiency (22), and familial hypercholesterolemia (23) in this population group. The presence of the same mutation in a family of non-European ancestry is interesting. The grandparents of the proband of Indian descent were born in the villages of Furus and Sakhrol near Khed, which is close to Bombay. There is no obvious relationship between any of the families of European descent and this Indian kindred. The ancestries of the other families with this mutation are English, Irish, German, Polish, and Dutch for many generations. Either this mutation has occurred spontaneously more than once at this position ofthe gene or one needs to postulate a common ancestor. However, the nucleotide sequence in this region is not typical for sequences rich in CpG dimers, which may be hotspots for mutations (24) .
At least three RFLPs have been described at the LPL gene locus (16, 17) . A total of eight DNA haplotypes are possible using a combination of these three RFLPs. 7 haplotypes were represented in this group of 44 unrelated probands with LPL deficiency. It is noteworthy that there was complete concordance between the residue 188 mutation and haplotype 1. Probands with two other previously described mutations have haplotypes 2 and 3 respectively (9. 10) ( Table III) . DNA haplotype analysis allowed us to address the question as to whether this single mutation has a common origin with geographical distribution after migration or whether the mutation has multicentric independent origins. The demonstration of a single haplotype underlying this mutation is preliminary evidence for a common origin for this mutation predating the spread of European and Indian populations. Haplotype 1 is also seen in probands who do not have this mutation and the population frequencies of these haplotypes are not known. The high frequency of this mutation in French Canadians and other persons with LPL deficiency allows development of a rapid screening test for this mutation using PCR and diges- tion with Ava II and assessment using either Southern blot analysis (Fig. 4) or running the amplified fragments on an acrylamide gel (Fig. 3) . Alternatively, a very rapid approach to diagnosis of this mutation can be undertaken using allele specific oligonucleotides for the normal and mutant alleles (data not shown). Human LPL deficiency recently has been classified at the protein level on the basis of the absence (Class I) or presence of defective enzyme protein, and whether it binds (Class II) or does not bind (Class III) to heparin (1 1). We have previously described the molecular basis of LPL deficiency in one Class I patient with no identifiable LPL activity nor mass (10). 7 of the 23 LPL-deficient patients previously reported were Class II (15) . DNA was available in four of these Class II individuals from three families and they were either homozygous (n = 1) or heterozygous (n = 3) for the 188-point mutation. 11 of the 13 patients in the present manuscript with the 188-point mutation were Class II. However, two patients had Class III protein defects. One of these patients was homozygous and one was heterozygous for the 188 mutation. (25) . The characterization of a common mutation underlying LPL deficiency in the French Canadian population and other persons with LPL deficiency will allow examination of the relationship of this specific genotype to the clinical phenotype.
The study of mutations in the LPL gene is likely to provide clues as to which regions of the LPL protein are crucial for specific functions. Furthermore, species conservation provides additional evidence for biological significance of certain regions. The two largest segments of the LPL protein that share complete homology between human, guinea pig, mouse, and cow are residues 178-210 in exon 5 and residues 287-320 which span part of exon 6 and 7 (6) . It has previously been demonstrated that the heparin binding site is likely to be located between amino acid residues 292 and 307 with the candidate segment being Lys292-Lys300, which has five positively charged amino acid residues and is encoded by exon 6 (8, 20) .
It is noteworthy that human and rat hepatic lipase share complete homology with residues 182-187 of human, guinea pig, mouse, and bovine LPL (6) . The predicted amino acid substitution ofglutamic acid for glycine extends the homology between abnormal (mutant) human LPL and human and rat hepatic lipase for an additional residue (Fig. 6) . It (26) . The mutation at residue 188 described in this manuscript does not affect the catalytic site but may influence catalysis by modulating accessibility of the substrate to the active site of hLPL by affecting tertiary structure. The three-dimensional structure of hLPL is likely to provide answers to some ofthese questions.
